Home > Publications Database > The cholinergic system modulates negative BOLD responses in the prefrontal cortex once electrical perforant pathway stimulation triggers neuronal afterdischarges in the hippocampus. > print

001     162924
005     20240320115515.0
024 7 _ |a pmc:PMC8795231
|2 pmc
024 7 _ |a 10.1177/0271678X211049820
|2 doi
024 7 _ |a pmid:34590894
|2 pmid
024 7 _ |a 0271-678X
|2 ISSN
024 7 _ |a 1559-7016
|2 ISSN
024 7 _ |a altmetric:115549204
|2 altmetric
037 _ _ |a DZNE-2021-01576
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Arboit, Alberto
|0 P:(DE-2719)2811871
|b 0
|e First author
|u dzne
245 _ _ |a The cholinergic system modulates negative BOLD responses in the prefrontal cortex once electrical perforant pathway stimulation triggers neuronal afterdischarges in the hippocampus.
260 _ _ |a London
|c 2022
|b Sage
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1655199038_923
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a (CC BY)
520 _ _ |a Repeated high-frequency pulse-burst stimulations of the rat perforant pathway elicited positive BOLD responses in the right hippocampus, septum and prefrontal cortex. However, when the first stimulation period also triggered neuronal afterdischarges in the hippocampus, then a delayed negative BOLD response in the prefrontal cortex was generated. While neuronal activity and cerebral blood volume (CBV) increased in the hippocampus during the period of hippocampal neuronal afterdischarges (h-nAD), CBV decreased in the prefrontal cortex, although neuronal activity did not decrease. Only after termination of h-nAD did CBV in the prefrontal cortex increase again. Thus, h-nAD triggered neuronal activity in the prefrontal cortex that counteracted the usual neuronal activity-related functional hyperemia. This process was significantly enhanced by pilocarpine, a mACh receptor agonist, and completely blocked when pilocarpine was co-administered with scopolamine, a mACh receptor antagonist. Scopolamine did not prevent the formation of the negative BOLD response, thus mACh receptors modulate the strength of the negative BOLD response.
536 _ _ |a 351 - Brain Function (POF4-351)
|0 G:(DE-HGF)POF4-351
|c POF4-351
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Cerebral blood volume (CBV)
|2 Other
650 _ 7 |a electrophysiology
|2 Other
650 _ 7 |a negative BOLD response
|2 Other
650 _ 7 |a pilocarpine
|2 Other
650 _ 7 |a scopolamine
|2 Other
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Cerebrovascular Circulation
|2 MeSH
650 _ 2 |a Hippocampus: blood supply
|2 MeSH
650 _ 2 |a Hippocampus: metabolism
|2 MeSH
650 _ 2 |a Hyperemia: metabolism
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Muscarinic Agonists: pharmacology
|2 MeSH
650 _ 2 |a Muscarinic Antagonists: pharmacology
|2 MeSH
650 _ 2 |a Neurons: metabolism
|2 MeSH
650 _ 2 |a Perforant Pathway: blood supply
|2 MeSH
650 _ 2 |a Perforant Pathway: metabolism
|2 MeSH
650 _ 2 |a Pilocarpine: pharmacology
|2 MeSH
650 _ 2 |a Prefrontal Cortex: blood supply
|2 MeSH
650 _ 2 |a Prefrontal Cortex: metabolism
|2 MeSH
650 _ 2 |a Rats
|2 MeSH
650 _ 2 |a Rats, Wistar
|2 MeSH
650 _ 2 |a Scopolamine: pharmacology
|2 MeSH
700 1 _ |a Krautwald, Karla
|0 P:(DE-2719)2278716
|b 1
|u dzne
700 1 _ |a Angenstein, Frank
|0 P:(DE-2719)2810456
|b 2
|e Last author
|u dzne
773 _ _ |a 10.1177/0271678X211049820
|g p. 0271678X2110498 -
|0 PERI:(DE-600)2039456-1
|n 2
|p 364-380
|t Journal of cerebral blood flow & metabolism
|v 42
|y 2022
|x 1559-7016
856 4 _ |u https://journals.sagepub.com/doi/10.1177/0271678X211049820?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
856 4 _ |u https://pub.dzne.de/record/162924/files/DZNE-2021-01576.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/162924/files/DZNE-2021-01576.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:162924
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2811871
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2278716
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2810456
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-351
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Brain Function
|x 0
914 1 _ |y 2022
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-10
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J CEREBR BLOOD F MET : 2021
|d 2022-11-10
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-10
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-10
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-10
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b J CEREBR BLOOD F MET : 2021
|d 2022-11-10
915 _ _ |a National-Konsortium
|0 StatID:(DE-HGF)0430
|2 StatID
|d 2022-11-10
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-04
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-10
920 1 _ |0 I:(DE-2719)1310004
|k AG Angenstein
|l Functional Neuroimaging
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1310004
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21